Close Menu

stock offering

The firm said that the overallotment option of 2.1 million shares was exercised, resulting in net proceeds of around $90.5 million from the offering.

The firm will use the funds to support ongoing testing and development of its trisomy 21 non-invasive, pre-natal test.

The firm is considering selling off its genetic testing and biomarker development business, including its CLIA lab.

Exact Sciences will use the funds to support clinical trials of its stool-based DNA colorectal cancer screening test.

Uses of the proceeds include funding clinical trials and obtaining FDA clearance for its sDNA colorectal cancer screening test.

The registration allows Exact Sciences to sell up to $150 million in securities, though it said that it has no immediate plans to do so.

Sequenom will not receive any of the proceeds of the sale of these shares by the selling stockholders, who purchased their shares through a private placement in May.

The money will help Wafergen commercially launch its high-throughput PCR system "imminently," according to a company official; and bolster the company's dwindling cash reserves in the interim.

The firm said that it will use funds from the offering to support commercialization of its SmartChip Real-Time PCR System including scale up of manufacturing capabilities for its instruments and chips.

Genomic Health has filed a replacement shelf registration for up to 10 million shares of its common stock in one or more offering.

Pages

A New Zealand minister says the country's genetic modification laws need to be re-examined to help combat climate change, the New Zealand Herald reports.

A new analysis finds some cancers receive more nonprofit dollars than others.

An Australian mother's conviction in the deaths of her children may be re-examined after finding that two of the children carried a cardiac arrhythmia-linked gene variant.

In Science this week: comparative analysis of sex differences in mammal gene expression, and more.